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Abstract Intracranial infection by gram-positive cocci is
commonly found after craniotomy. Norvancomycin was inde-
pendently developed in China, and had demonstrated thera-
peutic capability against gram-positive infection. This study
investigated the serum and cerebrospinal fluid (CSF) concen-
trations in patients that received intravenous injection of
norvancomycin after craniotomy. Patients with an indwelling
catheter in the operational area/ventricle after craniotomy
were administered norvancomycin by two approaches: (1)
The conventional group consisted of 14 cases that were in-
fused with 0.8 g norvancomycin for 1 h, every 12 h; (2) The
continuous administration group consisted of 14 cases that
were infused with 0.8 g norvancomycin for 1 h, and then
another 0.4 g for 11 h with extended infusion, followed by
continuous infusion of 0.4 g norvancomycin for 12 h. Samples
of serum and CSF were collected at different time-points to
measure norvancomycin levels after administration. In the
conventional and continuous administration groups, the peak
serum concentrations of norvancomycin were 55.52 ± 26.04
and 59.22 ± 41.88mg/L, respectively, while those at 24 h were
8.21 ± 6.04 and 8.01 ± 4.17 mg/L, respectively. Meanwhile,
peak CSF concentrations were 16.31 ± 11.15 and 8.82 ±
8.91 mg/L, respectively, while those at 24 h were 6.12 ±
2.34 and 6.24 ± 4.38 mg/L, respectively. This preliminary
study showed that for the early administration of standard
doses of norvancomycin post-neurosurgery, the CSF concen-
tration in both the conventional and continuous administration
groups reached or exceeded the 90 % minimum inhibitory
concentration (MIC90, 2 mg/L) of target bacteria such as
methicillin-resistant Staphylococcus aureus (MRSA).
Background
Intracranial infection after craniotomy, one of the most severe
postoperative complications, is a challenge in neurosurgical
treatment. Its high incidence impacts outcomes of patients
dramatically [1, 2]. The leading pathogens of surgical site
infections in postneurosurgical patients are Gram-positive
bacteria, especially S. aureus. Epidemiological studies of nos-
ocomial infection in our unit revealed that gram-positive bac-
teria were still common pathogens among intracranial infec-
tions after craniotomy, which mainly included methicillin-
resistant coagulase negative staphylococci (MRCoNS) and
Staphylococcus aureus [3, 4].
Vancomycin is a glycopeptides antibiotic that has been
widely used with activity primarily directed toward Gram-
positive pathogens, such as Staphylococcus aureus,
methicillin-resistant Staphylococcus aureus, Staphylococcus
epidermis, and Enterococcus faecalis [5, 6]. Therefore,
Vancomycin currently is commonly used as a first-line empir-
ic antibiotic therapy to prevent and treat these intracranial
infections [6, 7], despite its low CSF permeability.
Norvancomycin, a glycopeptide antimicrobial agent, was
independently developed by Chinese scientists, with a com-
parable antibacterial spectrum and antibacterial activities to
those of vancomycin [8]. Norvancomycin had been widely
used in neurosurgery in China, although pharmacokinetics-
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related studies conducted with this antimicrobial after craniot-
omy have been rarely reported. Our studies preliminarily con-
firmed that damage of the blood–brain barrier (BBB) by neu-
rosurgery was likely to increase the concentrations of vanco-
mycin and other antibiotics in the CSF of post-operative pa-
tients [9, 10].
This study was designed to investigate whether there
is an increased CSF penetration of norvancomycin into
the cerebrospinal fluid increases after BBB is impaired
following craniotomy, and whether continuous infusion
time affects drug concentration.
Study design
This was a prospective observational study.
Materials and methods
Patients
The study was approved by the Research Ethics Committee in
Tiantan Hospital, Capital Medical University (Beijing,
China,KY2014-014-02, June 4, 2014). Written informed con-
sent was obtained from all patients or their healthcare surro-
gates prior to enrollment in the study.
Inclusion criteria
Criteria for inclusion were neurosurgical patients (18–70 years
old, entering the ICU of Beijing Tiantan Hospital) with an
indwelling ventricular drainage pipe after neurological sur-
gery who were treated with norvancomycin for prevention
of intracranial infection between June and October in 2014.
Exclusion criteria
Criteria for exclusion were patients that had a history of
vancomycin or norvancomycin allergies; patients that
had received antibiotics against gram-positive bacteria
such as MRSA within 7 days before enrollment; patients
that were in an agonal state, deep coma, absence of
spontaneous breathing, or that had suffered from severe
dysfunction of the heart, lung, liver, kidney or other
organs; pregnant women in a perinatal stage; and pa-
tients that had to combine drug therapy, which might
increase drug toxicity, including aminoglycosides, salic-
ylates and blood-lipid regulation drugs, among others.
Administration norvancomycin and specimen collection
We maintained continuous observation of 14 patients with
conformance to the conventional drug administration, and
continuous observation of 14 cases of giving continuous dos-
ing. Norvancomycin solution was formulated using
norvancomycin (North China Pharmaceutical Group
Corporation, China, 400 mg/bottle) and 0.9 % normal saline.
Patients in the conventional group were infused with 0.8 g
norvancomycin for 1 h every 12 h. In addition, the continuous
administration group consisted of 14 cases that were adminis-
trated with 0.8 g norvancomycin for 1 h, with an extended
infusion of 0.4 g for 11 h, followed by continuous infusion
of 0.4 g for 12 h.
Venous blood and CSF were sampled from both
groups at the following time points after administration.
For the conventional group, 1–1.5 ml CSF and 2–2.5 ml
blood sample specimens were drawn at 1 h following
the start of an infusion of norvancomycin (ending) for
2, 3, 4, 6, 12, 13, 14 and 24 h. For the continuous
administration group, samples were drawn at 1 h after
administration (ending), and at 2, 3, 4, 6, 12 and 24 h,
following which, samples were rapidly centrifuged at 3
500 rpm for 3 min, where the supernatant was stored
frozen at −20 °C and transferred to the pharmacology
laboratory of the hospital as soon as possible, and then
stored in a −70 °C freezer and ultimately transferred to
the central laboratory of the Capital Medical University
for uniform testing.
Determination of norvancomycin concentration
Drugs and agents
We used standard vancomycin (i.e., as obtained from The
National Institute for the Control of Pharmaceutical and
Biological Products; batch number: 0360-200301, and equiv-
alent in dose to 1,007 U/mg), standard norvancomycin (The
National Institute for the Control of Pharmaceutical and
Biological Products; batch number: 130338-200303, and
equivalent to 914 U/mg, content 83.4 %), acetonitrile
(Fisher-Scientific, USA, chromatographic pure grade), and
analytical reagents, including potassium dihydrogen phos-
phate (KH2PO4), phosphate, perchloric acid and dichloro-
methane and deionized water (Millipore Direct+Q).
Instruments
We used high performance liquid chromatography (HPLC;
Waters, USA) using a 1525 high-pressure infusion system,
717 sampling system, equipped with a 2487 ultraviolet detec-
tor and a Waters Breeze chromatographic work station. We
also used an Eppendorf high-speed centrifuge, a Stuart turbine
mixer, and aMillipore Direct+Q pure-water system (Millipore
Ltd., United States).
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Experimental methods
Chromatographic conditions
The chromatographic column used was a Sapax C18 column,
USA (250 × 4.6 mm, 5 μm); the mobile phase was acetonitrile
0.05mol/L KH2PO4 buffer (pH = 3.3) at a ratio of 10:90, with
a measured wavelength of 230 nm, a velocity of 1.0 ml/min, a
column temperature of 30 °C, and a sample volume of 10 μl.
Preparation of control solution
For this preparation, 0.0164 g standard norvancomycin was
accurately weighed and placed into a 25 ml volumetric flask,
dissolved in purified water to a final concentration of
657.3 mg/L control solution, which was double diluted to
obtain serial stock solutions at concentrations of 328, 164,
80, 40, 20 and 10 μg/ml. Then, 0.0184 g vancomycin was
accurately weighed and placed into a 25 ml volumetric flask,
and then dissolved in purified water to obtain a 736.0 mg/ml
internal stock solution.
Management of plasma/cerebrospinal fluid specimens
In these studies, 0.5 ml plasma/cerebrospinal fluid was placed
into a test-tube, each of which had 60 μl of distilled water,
30 μl of an internal stock solution, and 170 μl 10 % perchloric
acid added. Then specimens were vortexed for 40 s and cen-
trifuged at 4 000 rpm for 10 min, from which the supernatant
was collected and 800 μl dichloromethane was added. This
was then vortexed for 1 min and centrifuged at 4000 rpm for
10 min, from which the supernatant was collected for
sampling.
Preparation of standard curves
In these studies, 0.5 ml of plasma/cerebrospinal fluid speci-
mens was accurately drawn into a test tube, each of which was
tested against the formulated serial stock solution of
norvancomycin to obtain norvancomycin mass concentrations
of 131.46, 65.73, 32.87, 16.43, 8.22, 4.11 and 2.05 μg/ml,
following which, the above mentioned management was ap-
plied to each test-tube, followed by testing according to preset
chromatographic conditions. The peak areas of the
norvancomycin and internal label were recorded, and then
regression analyses were performed using the weighted least
squares method by taking the ratio of the peak area of
norvancomycin over that of vancomycin as the horizontal
(X) axis, and the mass concentration of norvancomycin as
the longitudinal (Y) axis, thereby obtaining the regression
equation of the plasma as follows:
Y1 ¼ 22:896X1 þ 1:559; r1 ¼ 0:9994
Wherein the linear range of norvancomycin in the plasma
was 2.05–131.46 μg/ml and the lower limit of detection was
quantified as 2.05 μg/ml. The regression equation of CSF
specimens was as follows:
Y2 ¼ 51:192X2−6:533; r2 ¼ 0:996
Wherein the linear range of norvancomycin in CSF was
2.05–131.46 μg/ml and the lower limit of detection was quan-
tified as 2.05 μg/ml.
Statistical analyses
All the data were analyzed by Microsoft Office Excel 2013.
The norvancomycin concentrations in the serum and CSF
specimens at each time point were calculated, and the data
were expressed as mean ± standard deviation (x ± SD). The
concentration-time curves were drawn by taking the time as
the horizontal axis and the norvancomycin concentration as
the longitudinal axis. In addition, the ratios of the area under
the serum concentration curve over the MIC90 of MRSAwere
calculated, with the intention of comparing the relationships
of norvancomycin concentrations in both serum and CSF
specimens with the corresponding bacterial MIC90 at each
time-point, where the CSF permeability of the norvancomycin
was described using the ratio of CSF and serum concentration
peaks as well as the ratio of the areas under the curve.
Results
Twenty-eight patients were enrolled in the study, of which the
conventional group consisted of ten male and four female
study subjects with a mean age of 40 ± 17 years and a mean
weight of 73 ± 13 kg. Meanwhile the continuous administra-
tion group consisted of 11 males and three females, with a
mean age of 47 ± 14 years and a mean weight of 75 ± 10 kg.
Drugs that might increase drug toxicity including aminogly-
cosides, salicylates and blood-lipid regulatory drugs were not
given to any of the patients during administration. Basic in-
formation and clinical chemistry measurements are listed in
Tables 1, 2, and 3.
In the conventional group, serum levels of norvancomycin
peaked with a value of 55.52 ± 26.04 mg/L at 1 h after infu-
sion, which decreased to 10.62 ± 10.33 and 8.21 ± 6.04 mg/L
by 12 and 24 h, respectively. By contrast, levels of
norvancomycin in the CSF peaked with a value of 16.31 ±
11.15 mg/L by 3 h after administration, which decreased to
8.32 ± 5.16 and 6.12 ± 2.34mg/L by 12 and 24 h, respectively.
Meanwhile, in the continuous administration group, serum
levels of norvancomycin peaked with a value of 59.22
± 41.88 mg/L at 1 h after infusion, which decreased to 8.27
± 5.7 5 and 8.01 ± 4.17 mg/L by 12 and 24 h, respectively. By
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Table 1 Patient characteristics in
conventional groups Case Diagnosis Drainage tube
position
Antibiotics before administration
1 Central neurocytoma of left ventricle Ventricles Intraoperative 2 g ceferiaxonea
2 Glioblastomas of right forehead Operational cavity
drainage
Piperacillin sodium and Sulbactam
sodium: 5gQ8h
3 Right frontotemporal glioma Operational cavity
drainage
Intraoperative 1.5 g cefuroxime
4 Meningioma of left petrosal apex Subdural drainage Intraoperative 2 g ceferiaxone
5 Meningioma of left ventricle Operational cavity
drainage
Intraoperative 1 g ceferiaxone
6 Left cerebral arteriovenous malformation Hematoma cavity Ceftazidine: 2gQ8h
7 Bleeding of cerebellar glioma,
ventriculopuncture drainage
Ventricles Intraoperative 2 g ceferiaxone
8 Right frontal clear cell carcinoma Operational cavity
drainage
Intraoperative 2 g cefuroxime
9 Right frontotemporal glioma Operational cavity
drainage
Intraoperative 1.5 g cefuroxime
10 Fracture of left cerebral artery
aneurysm,SAH
Ventricles Ceftazidine: 2gQ8h
11 Left petroclival meningioma Operational cavity
drainage
Ceftazidine: 2gQ8h
12 Petroclival meningioma Operational cavity
drainage
Sulperazone: 1.5gQ6h
13 Central neurocytoma Operational cavity
drainage
14 Astrocytoma of thalamus and midbrain Ventricles Ceftazidine: 2gQ8h
aWell as cerebrospinal fluid penetration rate, ceftriaxone, widely used in China
Table 2 Patient characteristics in
continuous groups Case Diagnosis Drainage tube position Antibiotics before administration
1 Glioma in corpus callosum Operational cavity
drainage
Intraoperative 3 g cefuroxime
2 Parasellar meningioma Ventricles Intraoperative 1 g ceferiaxone




Intraoperative 2 g ceferiaxone
4 Central neurocytoma of right
ventricle
Ventricles Intraoperative 1 g ceferiaxone
5 Craniopharyngioma Operational cavity
drainage
Intraoperative 1.5 g cefuroxime




Piperacillin sodium and Sulbactam
sodium: 5gQ8h
7 Glioma of left tempus sinistrum Operational cavity
drainage
Ceftazidine: 2gQ8h
8 Neurilemmoma of left CPA Operational cavity
drainage
–
9 Craniopharyngioma Operational cavity
drainage
Intraoperative 1.5 g cefuroxime
10 Right frontal astrocytoma Subdural drainage –
11 Glioma of right thalamus Ventricles Ceftazidine: 2gQ8h
12 Craniopharynglioma Operational cavity
drainage
–
13 Deutocerebral glioma Operational cavity
drainage
14 Cerebellar meningioma Operational cavity
drainage
–
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contrast, the levels in the CSF peaked with a value of 8.82 ±
8.91 mg/L by 4 h after administration, which decreased to
3.28 ± 1.64 and 6.24 ± 4.39mg/L by 12 and 24 h, respectively.
In the conventional group, penetration of the CSF by the
drug that was obtained using the ratios of the peak concentra-
tions during the periods of 1–12 and 12–24 h were 29.4 and
16.7 %, respectively. By contrast, in the continuous adminis-
tration group, the CSF penetration by the drug that was ob-
tained by using the ratio of the peak concentration and the
ratio of the areas under the curves during the 1–12 and 12–
24 h were 14.9 and 34.3 %, respectively. In addition, taking
the MIC90 of the target bacteria like MRSA as 2 mg/L [6], the
areas under the serum concentration-time curve AUC0–24/
MIC90 were 193 and 181 in the conventional and continuous
administration groups, respectively. The drug concentrations
at various time-points are shown in Tables 4 and 5, and Figs. 1
and 2, which illustrate the concentration-time curves of the
norvancomycin in both groups.
Discussion
Although vancomycin does not penetrate the BBB with
high permeability, it is currently still a standard antibi-
otic protocol for treating intracranial infection caused by
MRSA and MRCoNS after craniotomy. Norvancomycin
has been considered to have a comparable antibacterial
spectrum and anti-bacterial activity to those described
for vancomycin. It had been widely used in preventing
and treating gram-positive infection in China, although
is not available therapeutically outside of China and
pharmacokinetics-related studies conducted with this an-
timicrobial are rarely reported [11], especially the per-
meability of norvancomycin through the BBB in neuro-
surgery patients.
It has been previously found that damage to the BBB
caused by neurosurgery tended to increase the vancomy-
cin concentration in the CSF in the early stages after cra-
niotomy, and intravenous infusion following a normal
dose of 1 g for 1 h showed a peak CSF concentration of
6.24 ± 3.46 mg/L and a nadir of 2.55 ± 1.13 mg/L, which
tended to achieve and exceed the 2 mg/L MIC90 of target
bacterial MRSA [12].
In this study, we applied a normal daily dose of
1.6 g norvancomycin in a similar population in the ear-
ly stages post-neurosurgery, and the results showed that
in both the conventional and continuous administration
groups, the CSF peak and trough concentrations were
likely to exceed those of vancomycin. However, wheth-
er the BBB permeability of norvancomycin was higher
than that of vancomycin warranted further investigation.
Referring to the literature [13–17], the MIC90 of
norvancomycin to MRSA and MRCoNS were 0.5–2 and 1–
4 mg/L, respectively, while that to Staphylococcus
epidermidis could be as high as 4 mg/L. Thus, this study
revealed that applying a normal dose of norvancomycin in
the early stages post-neurosurgery tended to obtain an
Table 4 Drug concentrations in the serum and CSF of the conventional
group
Time (hours) Norvancomycin (x ± SD)(n)(range)
Serum Cerebrospinal fluid
Prior to administration 0 0




































Table 3 Patient characteristics in
two groups Characteristics Conventional (N = 14) Continuous (N = 14) P value
Age, years 40 ± 17 47 ± 14 0.264
Gender, % male 71.4 (10/14) 78.6 (11/14) 1.000
Weight, kg 72.9 ± 12.6 75.4 ± 9.9 0.564
Creatinine, μg/ml 51.6 ± 12.6 53.8 ± 17.1 0.709
Day after neurosurgerya 1.3 ± 0.5 1.5 ± 1.1 0.596
aOne day represented the same day after neurosurgery
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effective concentration to the above target bacteria in CSF by
both conventional and continuous administration groups.
However, the drug concentration in the CSF tended to present
a decreasing trend with time, which might indicate that the
permeability of the drug had declined with gradual repair of
the BBB. Further studies are needed to investigate the tempo-
ral durability of the damage to the BBB and how long a higher
concentration of norvancomycin will be retained in CSF.
Also, a significant advantage of continuous administration
was not observed, which needs further investigation. In addi-
tion, this study adopted a normal dose (1.6 g/d) of
norvancomycin, which showed that an effective concentration
could be obtained in CSF in the early stages after craniotomy.
Previous results showed that the recommended dose of van-
comycin should be gradually increased in treating intracranial
infection because of the BMIC shift^ [18]. This is caused by
gradual repair of the BBB and deteriorating drug resistance.
However, whether it is necessary and safe to increase the dose
of norvancomycin in treating intracranial infection requires
further study.
In this study, a relative large standard deviation of
drug concentration was obtained, which might be asso-
ciated with the errors caused by deviation of sampling
time, transportation, storage and detection of the speci-
mens as well as a relatively small sample size.
However, more importantly, it might have been due to
a failure to administer a dose according to body weight
since the degree of BBB permeability might differ in
different patients. Therefore, studies with improved
quality control and a larger sample size are expected.
In summary, this study preliminarily investigated the serum
concentrations and CSF permeability with different adminis-
tration methods of norvancomycin. These studies also provid-
ed preliminary clinical pharmacological evidence for
assessing its value in preventing intracranial infection after
neurosurgery.
Conclusions
It indicated that the drug concentrations in the blood
and CSF could obtain and exceed the MIC90 of the
target bacteria, such as MRSA in both conventional
and continuous administration groups, when applying a
standard dose of norvancomycin in an early stage after
neurosurgery. However, we failed to observe significant
advantages of a continuous administration method over
the conventional administration method. This study is a
pilot research of norvancomycin used in neurosurgical
individuals, which needs to be confirmed by further
large-scale studies
Table 5 Drug levels in the serum and CSF of the continuous
administration group
Time (hours) Norvancomycin (x ± SD)(n)(range)
Serum Cerebrospinal fluid
Prior to administration 0 0






















































Fig. 2 CSF concentration-time curve of norvancomycin in the conven-

























Fig. 1 Serum concentration-time curve of norvancomycin in the conven-
tional and continuous group
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